UY32351A - Compuestos de pirimidinil indol para uso como inhibidores de atr - Google Patents
Compuestos de pirimidinil indol para uso como inhibidores de atrInfo
- Publication number
- UY32351A UY32351A UY0001032351A UY32351A UY32351A UY 32351 A UY32351 A UY 32351A UY 0001032351 A UY0001032351 A UY 0001032351A UY 32351 A UY32351 A UY 32351A UY 32351 A UY32351 A UY 32351A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirimidinil
- atr inhibitors
- indol compounds
- compounds
- indol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
Se proporcionan compuestos de pirimidinil indol de Fórmuls (I), o sales farmacéuticamente aceptables de los mismos, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13968108P | 2008-12-22 | 2008-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32351A true UY32351A (es) | 2010-07-30 |
Family
ID=41682867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032351A UY32351A (es) | 2008-12-22 | 2009-12-21 | Compuestos de pirimidinil indol para uso como inhibidores de atr |
Country Status (25)
Country | Link |
---|---|
US (1) | US20110053923A1 (es) |
EP (1) | EP2379530A1 (es) |
JP (1) | JP2012513388A (es) |
KR (1) | KR20110094342A (es) |
CN (1) | CN102325764A (es) |
AR (1) | AR074876A1 (es) |
AU (1) | AU2009332745A1 (es) |
BR (1) | BRPI0922475A2 (es) |
CA (1) | CA2750841A1 (es) |
CL (1) | CL2011001536A1 (es) |
CO (1) | CO6390107A2 (es) |
CR (1) | CR20110349A (es) |
CU (1) | CU20110137A7 (es) |
DO (1) | DOP2011000203A (es) |
EA (1) | EA201100971A1 (es) |
EC (1) | ECSP11011156A (es) |
IL (1) | IL213470A0 (es) |
MX (1) | MX2011006754A (es) |
NI (1) | NI201100130A (es) |
PE (1) | PE20110894A1 (es) |
SG (1) | SG171975A1 (es) |
TW (1) | TW201028410A (es) |
UY (1) | UY32351A (es) |
WO (1) | WO2010073034A1 (es) |
ZA (1) | ZA201105395B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2604066C2 (ru) | 2008-12-19 | 2016-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразина, используемые в качестве ингибиторов киназы atr |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
SG11201401093WA (en) * | 2011-09-30 | 2014-04-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
RS56673B1 (sr) | 2012-04-05 | 2018-03-30 | Vertex Pharma | Jedinjenja korisna kao inhibitori atr kinaze i kombinovane terapije koje ih koriste |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
CN107708690B (zh) * | 2015-02-27 | 2021-09-14 | 常山凯捷健生物药物研发(河北)有限公司 | 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用 |
EP3355926A4 (en) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS |
CN116211803A (zh) * | 2016-01-11 | 2023-06-06 | 梅里麦克制药股份有限公司 | 抑制共济失调毛细血管扩张和Rad3相关蛋白(ATR) |
WO2018153973A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors with parp inhibitors |
JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
UY37616A (es) | 2017-02-24 | 2018-09-28 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
US10421765B2 (en) | 2017-05-26 | 2019-09-24 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase |
PT3651768T (pt) | 2017-07-13 | 2024-03-20 | Univ Texas | Inibidores heterocíclicos da atr cinase |
CA3071760A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors |
EP3668839B1 (en) * | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
EP3720973A1 (en) | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
EP3753937B1 (en) * | 2018-02-07 | 2024-01-10 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Atr inhibitor and application thereof |
EP3765008B1 (en) | 2018-03-16 | 2023-06-07 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
JP7366125B2 (ja) | 2018-09-07 | 2023-10-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5-モルホリン-4-イル-ピラゾロ[4,3-b]ピリジン誘導体 |
US20210369724A1 (en) | 2018-10-16 | 2021-12-02 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20230018728A1 (en) * | 2019-11-21 | 2023-01-19 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
NZ518028A (en) | 1999-11-05 | 2004-03-26 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
ME00415B (me) | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
US20050277627A1 (en) | 2000-07-07 | 2005-12-15 | Arnould Jean C | Colchinol derivatives as vascular damaging agents |
EP1301498A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
DK1335906T3 (da) * | 2000-11-10 | 2007-02-05 | Hoffmann La Roche | Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander |
DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
KR20080052630A (ko) * | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Raf 억제제 화합물 및 그의 사용 방법 |
KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
US20090325957A1 (en) | 2006-08-24 | 2009-12-31 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
JP5534811B2 (ja) | 2006-08-24 | 2014-07-02 | アストラゼネカ アクチボラグ | 増殖性疾患の治療に有用なモルホリノピリミジン誘導体 |
BRPI0814503A2 (pt) * | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica |
AR067478A1 (es) | 2007-07-09 | 2009-10-14 | Astrazeneca Ab | Compuestos derivados de morfolina pirimidina |
-
2009
- 2009-12-21 TW TW098143945A patent/TW201028410A/zh unknown
- 2009-12-21 UY UY0001032351A patent/UY32351A/es not_active Application Discontinuation
- 2009-12-21 US US12/642,952 patent/US20110053923A1/en not_active Abandoned
- 2009-12-22 CN CN200980157610XA patent/CN102325764A/zh active Pending
- 2009-12-22 KR KR1020117016261A patent/KR20110094342A/ko not_active Application Discontinuation
- 2009-12-22 EP EP09795534A patent/EP2379530A1/en not_active Withdrawn
- 2009-12-22 BR BRPI0922475A patent/BRPI0922475A2/pt not_active IP Right Cessation
- 2009-12-22 WO PCT/GB2009/051755 patent/WO2010073034A1/en active Application Filing
- 2009-12-22 AR ARP090105074A patent/AR074876A1/es unknown
- 2009-12-22 PE PE2011001259A patent/PE20110894A1/es not_active Application Discontinuation
- 2009-12-22 JP JP2011541606A patent/JP2012513388A/ja active Pending
- 2009-12-22 MX MX2011006754A patent/MX2011006754A/es not_active Application Discontinuation
- 2009-12-22 AU AU2009332745A patent/AU2009332745A1/en not_active Abandoned
- 2009-12-22 SG SG2011041027A patent/SG171975A1/en unknown
- 2009-12-22 EA EA201100971A patent/EA201100971A1/ru unknown
- 2009-12-22 CA CA2750841A patent/CA2750841A1/en not_active Abandoned
-
2011
- 2011-06-09 IL IL213470A patent/IL213470A0/en unknown
- 2011-06-21 CL CL2011001536A patent/CL2011001536A1/es unknown
- 2011-06-22 NI NI201100130A patent/NI201100130A/es unknown
- 2011-06-22 DO DO2011000203A patent/DOP2011000203A/es unknown
- 2011-06-22 EC EC2011011156A patent/ECSP11011156A/es unknown
- 2011-06-22 CR CR20110349A patent/CR20110349A/es unknown
- 2011-06-22 CU CU20110137A patent/CU20110137A7/es unknown
- 2011-06-29 CO CO11081450A patent/CO6390107A2/es not_active Application Discontinuation
- 2011-07-21 ZA ZA2011/05395A patent/ZA201105395B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012513388A (ja) | 2012-06-14 |
BRPI0922475A2 (pt) | 2017-06-06 |
EP2379530A1 (en) | 2011-10-26 |
IL213470A0 (en) | 2011-07-31 |
AR074876A1 (es) | 2011-02-16 |
CL2011001536A1 (es) | 2011-10-14 |
AU2009332745A1 (en) | 2011-06-30 |
EA201100971A1 (ru) | 2012-01-30 |
ECSP11011156A (es) | 2011-07-29 |
PE20110894A1 (es) | 2012-01-18 |
US20110053923A1 (en) | 2011-03-03 |
CU20110137A7 (es) | 2012-01-31 |
TW201028410A (en) | 2010-08-01 |
SG171975A1 (en) | 2011-07-28 |
CO6390107A2 (es) | 2012-02-29 |
DOP2011000203A (es) | 2011-07-15 |
CN102325764A (zh) | 2012-01-18 |
CR20110349A (es) | 2011-08-05 |
ZA201105395B (en) | 2012-03-28 |
CA2750841A1 (en) | 2010-07-01 |
NI201100130A (es) | 2012-03-19 |
WO2010073034A1 (en) | 2010-07-01 |
MX2011006754A (es) | 2011-07-20 |
KR20110094342A (ko) | 2011-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32351A (es) | Compuestos de pirimidinil indol para uso como inhibidores de atr | |
UY32203A (es) | Amino pirimidinas y su uso en terapia | |
UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
CR11857A (es) | Compuestos pirazolicos 436 | |
CR11641A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
NI201000004A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
ECSP109856A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
CR10573A (es) | Derivados del pirazol como inhibidores del citocromo p450 | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
ECSP10010664A (es) | Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas | |
UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
UY31839A (es) | Compuestos | |
UY32694A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
UY32316A (es) | Derivados de piperidina utiles en el tratamiento de infecciones bacterianas | |
CR11584A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
UY30982A1 (es) | Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
CU23604B7 (es) | Compuestos terapéuticos | |
CU20100250A7 (es) | Compuestos pirazólicos 436 | |
CU20100172A7 (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20190121 |